These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27825132)

  • 21. The role of p95HER2 in trastuzumab resistance in breast cancer.
    Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
    J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
    Kim YJ; Sung D; Oh E; Cho Y; Cho TM; Farrand L; Seo JH; Kim JY
    Cancer Lett; 2018 Jan; 412():118-130. PubMed ID: 29080749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NES1/KLK10 promotes trastuzumab resistance via activation of PI3K/AKT signaling pathway in gastric cancer.
    Tang L; Long Z; Zhao N; Feng G; Guo X; Yu M
    J Cell Biochem; 2018 Aug; 119(8):6398-6407. PubMed ID: 29231994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.
    Singla H; Ludhiadch A; Kaur RP; Chander H; Kumar V; Munshi A
    Eur J Med Chem; 2017 Dec; 142():316-327. PubMed ID: 28800870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells.
    DiScala M; Najor MS; Yung T; Morgan D; Abukhdeir AM; Cobleigh MA
    PLoS One; 2020; 15(6):e0234146. PubMed ID: 32525891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Potential Target Genes of Borneol in Increasing Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer: Bioinformatics and In Vitro Studies.
    Lestari IA; Putra IMR; Fatimah N; Ujiantari NSO; Putri DDP; Hermawan A
    Asian Pac J Cancer Prev; 2024 May; 25(5):1623-1634. PubMed ID: 38809634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.
    Díaz-Rodríguez E; Pérez-Peña J; Ríos-Luci C; Arribas J; Ocaña A; Pandiella A
    Cancer Lett; 2019 Jul; 453():34-44. PubMed ID: 30928382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer.
    Yang T; Fu Z; Zhang Y; Wang M; Mao C; Ge W
    Biomed Pharmacother; 2020 Sep; 129():110465. PubMed ID: 32887021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment.
    Abduyev Z; Altundag K
    J BUON; 2019; 24(5):2208. PubMed ID: 31786900
    [No Abstract]   [Full Text] [Related]  

  • 32. Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer.
    Sun Z; Zhang C; Wang T; Shi P; Tian X; Guo Y
    J Cancer Res Ther; 2019; 15(4):933-940. PubMed ID: 31436255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
    Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
    Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
    Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
    Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting ITGβ3 to Overcome Trastuzumab Resistance through Epithelial-Mesenchymal Transition Regulation in HER2-Positive Breast Cancer.
    Boz Er AB; Er I
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
    Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
    Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer.
    von der Heyde S; Wagner S; Czerny A; Nietert M; Ludewig F; Salinas-Riester G; Arlt D; Beißbarth T
    PLoS One; 2015; 10(2):e0117818. PubMed ID: 25710561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells.
    Murad R; Avanes A; Ma X; Geng S; Mortazavi A; Momand J
    Gene; 2021 Oct; 799():145808. PubMed ID: 34224831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
    Berns K; Horlings HM; Hennessy BT; Madiredjo M; Hijmans EM; Beelen K; Linn SC; Gonzalez-Angulo AM; Stemke-Hale K; Hauptmann M; Beijersbergen RL; Mills GB; van de Vijver MJ; Bernards R
    Cancer Cell; 2007 Oct; 12(4):395-402. PubMed ID: 17936563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.